eli lilly glp-1 drugs is selling $12.9 billion of every three months — and expects to sell even more Eli Lilly Gets Speedy FDA
Description
This is a synthetic tri-agonist peptide designed for laboratory research focused on multi-pathway metabolic signaling
1 Glucagon-like peptide 1 (GLP-1) receptor agonists are a class of medications that were first approved in 2005 for type 2 diabetes (T2D)
As with any medicine, there is a possibility of unwanted effects
Diabetes 65 , 14871489 (2016)
Just know this has not yet been evaluated in clinical trials
Low blood sugar can occur at any time, particularly if doses are not properly adjusted for food intake, exercise, or changes in other medications
